Form 4: MariMed CEO Jon Levine Executes RSU Vesting

CEO Jon Levine acquired 75,000 shares of MariMed common stock through the vesting of restricted stock units.

Summary

• CEO Jon Levine acquired 75,000 shares of common stock upon the vesting of restricted stock units (RSUs) on May 7, 2026.
• The company withheld 25,988 shares to satisfy tax obligations related to the vesting event.
• Following these transactions, the CEO holds 21,207,986 shares directly and maintains an indirect interest in 6,684,640 shares via the Jon Levine Family Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation with no material impact on the company's operational outlook.

Positives

• The transaction reflects the vesting of equity compensation, aligning the CEO's interests with long-term shareholder value.

Negatives

• The withholding of 25,988 shares for tax purposes represents a minor reduction in the total direct share count.

Risks

• The CEO's significant ownership stake (over 27 million shares combined) creates high concentration risk for the company's governance and stock liquidity.

Future Outlook

The filing notes that the remaining RSUs from the March 2023 grant are scheduled to vest on November 7, 2026.

Management Comments

• The reporting person disclaims beneficial ownership of the 6,684,640 shares held in the Jon Levine Family Trust.

Industry Context

StockSavvy.ai notes that insider equity vesting is a standard corporate governance practice in the cannabis sector, though the high concentration of ownership by the CEO is notable for a company of this size.

Comparison to Industry Standards

• The use of RSU vesting for executive compensation is consistent with standard practices among mid-cap cannabis firms like Curaleaf or Trulieve.
• The tax withholding mechanism is a standard administrative procedure for equity-based compensation.

Related Party Transactions

• The reporting person maintains an indirect interest in 6,684,640 shares held by the Jon Levine Family Trust.

Stakeholder Impact

• Minimal impact on shareholders as this is a pre-planned equity compensation event.

Next Steps

• Vesting of remaining RSUs on November 7, 2026.

Key Dates

Keywords

MariMed, MRMD, Insider Trading, Form 4, Equity Compensation, Jon Levine